Dual molecular delivery of oligonucleotides and peptide containing conjugates
US-2017189441-A1 · Jul 6, 2017 · US
Peptide containing conjugates for dual molecular delivery of oligonucleotides
US10239957B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10239957-B2 |
| Application number | US-201415033731-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 3, 2014 |
| Priority date | Nov 6, 2013 |
| Publication date | Mar 26, 2019 |
| Grant date | Mar 26, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein is a peptide containing conjugate comprising (P) c -(L) d -(G) e , wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L) a -(G) b , wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
First claim
Opening claim text (preview).
What is claimed is: 1. A peptide containing conjugate comprising: wherein P is a peptide selected from Table 2a: SEQ ID Peptide Sequence NO: CIFGAIAGFIKNIWEGLI SEQ ID NO: 26 CFFGAIWEFIHSIL SEQ ID NO: 74 CGIFEAIAGLLKNIFK SEQ ID NO: 82 CGIGAVLKVLTTGLPALISWIKRKRQQ SEQ ID NO: 255 CGFFGEIAELIEEGLKNLIDWWNG SEQ ID NO: 543 CGFFGEIAELIWEGLKNLIDWWNG SEQ ID NO: 935 CGLFGEIEELIEEGLENLIDWANG SEQ ID NO: 1078 CFLEELWELLEHLL SEQ ID NO: 1248 AC-CFLEELWELLEHLL SEQ ID NO: 1391 CGLLEEIEELLEEGLENLIDWWNS SEQ ID NO: 1403 CFLEELWGLLEHLL SEQ ID NO: 1419 CLELWLEHLFLELE SEQ ID NO: 1489 CGLFAEIEELLEEGLENLIDWWNG SEQ ID NO: 1516 CGLFGEIEELIEEGLE-CIT-LIDWWNG SEQ ID NO: 1517 CGLFGEIEELIEEGLENLIDWWNE SEQ ID NO: 1518 CGLL-AIB-EIEELLEEGLENLIDWWNS SEQ ID NO: 1628 CGLFGHIHHLIHHGLHNLIDWWNG SEQ ID NO: 1631 CGLFGEIHHLIHHGLHNLIDWWNG SEQ ID NO: 1632 CGLFGEIHHLIHHGLENLIDWWNG SEQ ID NO: 1633 CGLFGEIHELIHHGLENLIDWWNG SEQ ID NO: 1634 CGFFGEIAELIEEGLKNLIDWGNG SEQ ID NO: 1643 CGLFGEIEELIEEGLENLIDWSNG SEQ ID NO: 1645 CGLFGEIEELIEEGLENLIDWPNG SEQ ID NO: 1647 CGLFGEIEELIEEGLENLIDWHNG SEQ ID NO: 1648 CGLFGEIEELIEEGLENLIDWQNG SEQ ID NO: 1649 CGLFGEIEELIEEGLENLIDWENG SEQ ID NO: 1650 CGLFEEIAELIEEGLENLIDWGNG SEQ ID NO: 1651 CELFEELAELLWEGLENLIDWGNS SEQ ID NO: 1652 CGLFGEIAELIWEGLENLIDWGNG SEQ ID NO: 1653 CGLLEEIEELLEEGLENLIDWGNS SEQ ID NO: 1654 CGLFGEIEELIEEGLENLIDWNNG SEQ ID NO: 1657 CGLFAEIEELLEEGLENLIDWGNG SEQ ID NO: 1660 CGLFGEIEELIEEGLENLIDWONG SEQ ID NO: 1662 CGLFGEIEELIEEGLENLIDWDNG SEQ ID NO: 1696 GLFGEIEELIECGLENLIDWGNG SEQ ID NO: 1697 CGLFGEIEELIEEGLENLIDW-AIB-NG SEQ ID NO: 1701 AC-GLLEEIEELLEEGLENLIDWWNSC SEQ ID NO: 1702 GLLEEIEELLEEGLENLAELAEALEALAAGGSC SEQ ID NO
Assignees
Inventors
Classifications
containing a localisation/targetting motif · CPC title
DNA sequences coding for fusion proteins · CPC title
Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin} · CPC title
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
Fusion polypeptide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10239957B2 cover?
- Disclosed herein is a peptide containing conjugate comprising (P) c -(L) d -(G) e , wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each …
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07K19/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).